Home - ExecEdge

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

By Karen Roman VERAXA Biotech AG (Nasdaq: VRXA) said it started cell line development for its lead BiTAC T-cell engager program, collaborating with ATUM to...

VERAXA Biotech Stock in Focus as Lead Cancer Program Reaches Development Milestone

SkylineDx’s Merlin CP-GEP Granted FDA Breakthrough Device Designation

Imviva Biotech Granted FDA IDE Authorization for Cancer Treatment Trial

Tackling the AI Security Crisis: Pax8’s Rob Belgrave and SentinelOne’s Steve Stone, Live from Pax8 Beyond 2026